JP2024519922A5 - - Google Patents
Info
- Publication number
- JP2024519922A5 JP2024519922A5 JP2023571978A JP2023571978A JP2024519922A5 JP 2024519922 A5 JP2024519922 A5 JP 2024519922A5 JP 2023571978 A JP2023571978 A JP 2023571978A JP 2023571978 A JP2023571978 A JP 2023571978A JP 2024519922 A5 JP2024519922 A5 JP 2024519922A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- nucleic acid
- acid encoding
- isolated polynucleotide
- polynucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163191458P | 2021-05-21 | 2021-05-21 | |
| US63/191,458 | 2021-05-21 | ||
| US202263322182P | 2022-03-21 | 2022-03-21 | |
| US63/322,182 | 2022-03-21 | ||
| PCT/US2022/030359 WO2022246266A1 (en) | 2021-05-21 | 2022-05-20 | Base editing of transthyretin gene |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024519922A JP2024519922A (ja) | 2024-05-21 |
| JP2024519922A5 true JP2024519922A5 (enExample) | 2025-05-27 |
Family
ID=84141870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023571978A Pending JP2024519922A (ja) | 2021-05-21 | 2022-05-20 | トランスサイレチン遺伝子の塩基編集 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240124536A1 (enExample) |
| EP (1) | EP4352216A4 (enExample) |
| JP (1) | JP2024519922A (enExample) |
| KR (1) | KR20240010720A (enExample) |
| AU (1) | AU2022275546A1 (enExample) |
| CA (1) | CA3220738A1 (enExample) |
| WO (1) | WO2022246266A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20260094824A (ko) | 2023-10-25 | 2026-06-23 | 씨에스피씨 종콰이 팔마씨우티컬 테크놀로지 (스자좡) 컴퍼니 리미티드 | 고효율, 저오프타겟 유전자 편집 도구 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11866727B2 (en) * | 2015-11-06 | 2024-01-09 | Crispr Therapeutics Ag | Materials and methods for treatment of glycogen storage disease type 1A |
| ES3030658T3 (en) * | 2016-03-30 | 2025-07-01 | Intellia Therapeutics Inc | Lipid nanoparticle formulations for crispr/cas components |
| WO2018007871A1 (en) * | 2016-07-08 | 2018-01-11 | Crispr Therapeutics Ag | Materials and methods for treatment of transthyretin amyloidosis |
| TWI904069B (zh) * | 2017-09-29 | 2025-11-11 | 美商英特利亞醫療公司 | 用於ttr基因編輯及治療attr澱粉樣變性之組合物及方法 |
| KR102959497B1 (ko) * | 2018-05-11 | 2026-05-04 | 빔 테라퓨틱스, 인크. | 프로그래밍가능한 염기 편집기 시스템을 이용하여 병원성 돌연변이를 억제하는 방법 |
| KR102853088B1 (ko) * | 2018-05-11 | 2025-09-02 | 빔 테라퓨틱스, 인크. | 프로그래밍가능한 염기 편집기 시스템을 이용하여 단일염기다형성을 편집하는 방법 |
| WO2019226953A1 (en) * | 2018-05-23 | 2019-11-28 | The Broad Institute, Inc. | Base editors and uses thereof |
| CN114040970B (zh) * | 2019-02-13 | 2024-09-27 | 比姆医疗股份有限公司 | 使用腺苷脱氨酶碱基编辑器编辑疾病相关基因的方法，包括遗传性疾病的治疗 |
| US20220098593A1 (en) * | 2019-02-13 | 2022-03-31 | Beam Therapeutics Inc. | Splice acceptor site disruption of a disease-associated gene using adenosine deaminase base editors, including for the treatment of genetic disease |
| KR20220004648A (ko) * | 2019-03-28 | 2022-01-11 | 인텔리아 테라퓨틱스, 인크. | Ttr 가이드 rna, 및 rna-가이드 dna 결합제를 암호화하는 폴리뉴클레오티드를 포함하는 조성물 및 방법 |
| MX2021011690A (es) * | 2019-03-28 | 2022-01-06 | Intellia Therapeutics Inc | Composiciones y métodos para la edición del gen ttr y el tratamiento de la amiloidosis attr que comprende un corticosteroide o uso de este. |
| EP4259792A1 (en) * | 2020-12-11 | 2023-10-18 | Intellia Therapeutics, Inc. | Polynucleotides, compositions, and methods for genome editing involving deamination |
| CN117729931A (zh) * | 2021-05-14 | 2024-03-19 | 比姆医疗股份有限公司 | 用于治疗转甲状腺素蛋白淀粉样变性的组合物和方法 |
-
2022
- 2022-05-20 CA CA3220738A patent/CA3220738A1/en active Pending
- 2022-05-20 EP EP22805626.3A patent/EP4352216A4/en active Pending
- 2022-05-20 WO PCT/US2022/030359 patent/WO2022246266A1/en not_active Ceased
- 2022-05-20 JP JP2023571978A patent/JP2024519922A/ja active Pending
- 2022-05-20 KR KR1020237043681A patent/KR20240010720A/ko active Pending
- 2022-05-20 AU AU2022275546A patent/AU2022275546A1/en active Pending
-
2023
- 2023-11-20 US US18/515,118 patent/US20240124536A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210380987A1 (en) | Crispr/cas-related methods and compositions for treating cystic fibrosis | |
| JP2024038327A5 (enExample) | ||
| JP4063326B2 (ja) | 非天然ヌクレオチドを有するキメラ突然変異性ベクター | |
| CN116209770A (zh) | 用于调控基因组的改善的方法和组合物 | |
| JP2022546608A5 (enExample) | ||
| KR20210029772A (ko) | 유전자 편집을 위한 변형된 가이드 rna | |
| JP2021500864A5 (enExample) | ||
| CN117821458A (zh) | 用于治疗β-血红蛋白病的CRISPR/CAS相关方法和组合物 | |
| JP2022545950A5 (enExample) | ||
| EP3365447A1 (en) | Crispr/cas-related methods and compositions for treating hepatitis b virus | |
| EP4041894A1 (en) | COMPOSITIONS AND METHODS FOR MODULATING HEPATOCYTE NUCLEAR FACTOR 4-ALPHA (HNF4a) GENE EXPRESSION | |
| CN120435553A (zh) | 合成多肽及其用途 | |
| AU722909B2 (en) | Method for the production of a therapeutic DNA | |
| US11891635B2 (en) | Nucleic acid sequence replacement by NHEJ | |
| CA3173528A1 (en) | Compositions and methods for modulating forkhead box p3 (foxp3) gene expression | |
| KR20260032655A (ko) | Hbv 유전자 발현의 후성유전학적 조절을 위한 조성물 및 방법 | |
| US20220288237A1 (en) | Compositions and methods for modulating apolipoprotein b (apob) gene expression | |
| JP2020528735A (ja) | 反復伸長変異のためのゲノム編集システム | |
| EP3868887A1 (en) | Novel virus vector and methods for producing and using same | |
| CN114072518A (zh) | 用于治疗地中海贫血或镰状细胞病的方法和组合物 | |
| CN110551763A (zh) | CRISPR/SlutCas9基因编辑系统及其应用 | |
| WO2026085201A2 (en) | Base editing to correct inborn errors of immunity | |
| CN120944971A (zh) | 腺嘌呤碱基编辑器中腺嘌呤脱氨酶的静电重塑及其在全基因组消除脱靶效应的应用 | |
| EP4716741A2 (en) | Compositions and methods for reducing cxcl9, cxcl10, and cxcl11 gene expression | |
| WO2026067818A1 (zh) | 一种用于调控SCN1A基因mRNA和蛋白表达的方法和化合物 |